These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 36692405)
1. The Feasibility of Abbreviated MRI for Active Surveillance of Hepatocellular Carcinoma. Kim H Radiology; 2023 Apr; 307(2):e223113. PubMed ID: 36692405 [No Abstract] [Full Text] [Related]
2. Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Outcomes of early treatment and watchful waiting. Woo JH; Song KD; Kim SH Eur Radiol; 2017 Oct; 27(10):4406-4414. PubMed ID: 28386720 [TBL] [Abstract][Full Text] [Related]
3. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. Demirtas CO; Gunduz F; Tuney D; Baltacioglu F; Kani HT; Bugdayci O; Alahdab YO; Ozdogan OC Eur J Gastroenterol Hepatol; 2020 Apr; 32(4):517-523. PubMed ID: 31524775 [TBL] [Abstract][Full Text] [Related]
4. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722 [TBL] [Abstract][Full Text] [Related]
5. PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. Parikh ND Am J Gastroenterol; 2017 Nov; 112(11):1632-1633. PubMed ID: 28972597 [No Abstract] [Full Text] [Related]
6. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. Park HJ; Jang HY; Kim SY; Lee SJ; Won HJ; Byun JH; Choi SH; Lee SS; An J; Lim YS J Hepatol; 2020 Apr; 72(4):718-724. PubMed ID: 31836549 [TBL] [Abstract][Full Text] [Related]
7. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Whang S; Choi MH; Choi JI; Youn SY; Kim DH; Rha SE Eur Radiol; 2020 Aug; 30(8):4150-4163. PubMed ID: 32166493 [TBL] [Abstract][Full Text] [Related]
8. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190 [TBL] [Abstract][Full Text] [Related]
9. Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening. Kutaiba N; Ardalan Z J Hepatol; 2021 Nov; 75(5):1258-1259. PubMed ID: 34242701 [No Abstract] [Full Text] [Related]
10. Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening". Gupta P; Sharma V; Kalra N J Hepatol; 2021 Nov; 75(5):1259-1260. PubMed ID: 34437909 [No Abstract] [Full Text] [Related]
11. State of the art in magnetic resonance imaging of hepatocellular carcinoma. Horvat N; Monti S; Oliveira BC; Rocha CCT; Giancipoli RG; Mannelli L Radiol Oncol; 2018 Nov; 52(4):353-364. PubMed ID: 30511939 [TBL] [Abstract][Full Text] [Related]
12. Abbreviated Liver Magnetic Resonance Imaging Protocols and Applications. Altinmakas E; Taouli B Radiol Clin North Am; 2022 Sep; 60(5):695-703. PubMed ID: 35989038 [TBL] [Abstract][Full Text] [Related]
14. Abbreviated MRI for HCC surveillance: is it ready for clinical use? Vietti Violi N; Taouli B Eur Radiol; 2020 Aug; 30(8):4147-4149. PubMed ID: 32394280 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. Marks RM; Ryan A; Heba ER; Tang A; Wolfson TJ; Gamst AC; Sirlin CB; Bashir MR AJR Am J Roentgenol; 2015 Mar; 204(3):527-35. PubMed ID: 25714281 [TBL] [Abstract][Full Text] [Related]
16. Size discrepancy between sonographic and computed tomographic/magnetic resonance imaging measurement of hepatocellular carcinoma: the necessity of tumor size measurement standardization. Cha MJ; Lee MW; Cha DI; Kim JH; Rhim H; Cho YK; Kim YJ; Choi D; Kim YS; Lim HK J Ultrasound Med; 2013 Oct; 32(10):1703-9. PubMed ID: 24065250 [TBL] [Abstract][Full Text] [Related]
17. Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis. Duncan JK; Ma N; Vreugdenburg TD; Cameron AL; Maddern G J Magn Reson Imaging; 2017 Jan; 45(1):281-290. PubMed ID: 27299482 [TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced ultrasound in the characterization of hepatocellular carcinomas treated by ablation: comparison with contrast-enhanced magnetic resonance imaging. Qu P; Yu X; Liang P; Cheng Z; Han Z; Liu F; Yu J Ultrasound Med Biol; 2013 Sep; 39(9):1571-9. PubMed ID: 23830098 [TBL] [Abstract][Full Text] [Related]
19. Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance. Park HJ; Seo N; Kim SY Korean J Radiol; 2022 Jun; 23(6):598-614. PubMed ID: 35434979 [TBL] [Abstract][Full Text] [Related]
20. [Hepatocellular carcinoma and cholangiocarcinoma]. Rauchfuss F; Scheuerlein H; Götz M; Dittmar Y; Voigt R; Heise M; Settmacher U Chirurg; 2010 Oct; 81(10):941-52; quiz 953. PubMed ID: 20827454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]